Published in Pharma Investments, Ventures and Law Weekly, August 28th, 2005
Under the terms of the agreement, Bionutrics will purchase 100% of Kirk for $12 million in a combination of cash and debt.
Ronald H. Lane, PhD, Bionutrics' chairman and CEO stated, "This acquisition is an important step in the commercialization of Bionutrics' drug technology and further execution of our business plan. Kirk has relationships with some of the world's largest drug retailers and generic pharmaceutical companies and a growing manufacturing presence in the industry.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly